Short Interest in Innovent Biologics, Inc. (OTCMKTS:IVBXF) Rises By 13.3%

Innovent Biologics, Inc. (OTCMKTS:IVBXF) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 2,971,000 shares, an increase of 13.3% from the May 31st total of 2,622,200 shares. Based on an average daily volume of 7,800 shares, the days-to-cover ratio is presently 380.9 days.

Innovent Biologics Trading Down 5.9 %

Shares of OTCMKTS IVBXF traded down $0.29 during midday trading on Monday, hitting $4.71. The company’s stock had a trading volume of 7,800 shares, compared to its average volume of 139,206. The business’s fifty day simple moving average is $4.84 and its two-hundred day simple moving average is $4.87. Innovent Biologics has a 1 year low of $3.55 and a 1 year high of $6.41.

About Innovent Biologics

Innovent Biologics, Inc, a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor.